Expression of Aberrant CD Markers in Acute Leukemia:Retrospective Study in South Egypt Cancer Institute
NCT ID: NCT03743909
Last Updated: 2018-11-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2019-01-01
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Correlation between this expression and outcome of the patient.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer
NCT04720508
Concordance of the Biology of Primary Breast Carcinoma and the Biology of Recurrence .
NCT07275203
Frequency of SARS COVID-19 Infection Among Malignant Patients at South Egypt Cancer Institute
NCT05465759
Effectiveness of Introducing Ultra-High B-Value Diffusion-Weighted Imaging as a Modified Abbreviated Protocol for Breast Cancer Detection
NCT06970288
Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy
NCT05301790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Acute leukemia is a cloned expansion of tumor cells in bone marrow, blood or other tissues. The acute leukemia is classified as acute myeloid leukemia (AML) due to defective differentiation of myeloid lineage or acute lymphoid leukemia (ALL) due to defective differentiation of lymphoid lineage(Olaniyi JA et al., 2011).
Leukemia is diagnosed by morphology and cytochemical examination of blast cells, immunophenotyping, cytogenetic and molecular genetics. (Hazarika M et al., 2015 ). immunophenotyping is mandatory for the diagnosis of hematolymphoid malignancies (Craig FE et al., 2008)
Immunophenotyping of leukemia cells plays crucial role in identification of leukemia cell line, assesment of maturation stage and finding possible aberrant antigens which in turn serves for individual treatment monitoring and detection of residual disease(Kahng J et al.,2008).
Immunophenotyping identifies cell surface/CD markers(cluster of differentiation), expressed at different stages of cell development, by applying monoclonal antibodies against them helps in the diagnosis and classification of leukemia. The morphologically similar blast cells can be easily differentiated by immunophenotyping on the basis of expression and different CD markers (Angelescu S et al.,2012).
Aberrant expression of CD markers has been observed in several cases of acute leukemia(Chang Y et al., 2011).
Aberrant phenotype is a phenomenon in which lymphoid-associated and other myeloid lineage markers expressed in myeloblasts or myeloid-associated markers expressed in lymphoblasts. Aberrant phenotype incidence has been reported in both ALL and AML with varying frequencies as high as 88%(Macedo A et al.,1995).
The aberrant phenotypes are classified into different types: co-expression of lymphoid-associated antigens or lineage infidelity; asynchronous antigen expression, in which early antigens are coexpressed with more mature ones; or antigen overexpression and existence of abnormal light scatter patterns(Gert Ossenkoppele et al., 2011).
Presence or absence of these aberrant markers may also be associated with poor or favorable prognosis(Alhan C et al., 2014).
Several studies have reported correlations of aberrantly expressed markers with clinical outcome in AML. For example, CD7 and CD25 expression has been associated with poor prognosis in normal karyotype AML(Cerny J et al.,2013) The IL3 receptor alfa (CD123) is overexpressed in 45% of AML patients, and this higher expression has also been associated with poor outcome (Riccioni R et al.,2002).
CD13 and CD33 are most frequently associated with aberrant myeloid expression in ALL (Hrusák O et al,2002).Studies indicate that aberrant immunophenotypic expression can decrease the time of remission and survival in children with ALL (Kurec et al., 1991).Aberrant expression of CD13 in ≥ 5% of blasts of adult patients with ALL is an adverse prognostic factor,that should be considered for more aggressive treatment(Dalal BI1 et al.,2014).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with aberrant CD markers
by flowcytometry from hospital information system
No interventions assigned to this group
patients without aberrant CD markers
by flowcytometry from hospital information system
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mervat Awad Mohamed Ibrahim
South Egypt cancer institute Assuit university
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
acute leukemia
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.